Exaggerated Drug Claims

Paul Ernsberger says that inflated mortality statistics are based on the works of pharmacoeconomics experts. “These experts create cost-benefit analyses which are part of all drug applications to the FDA. These self-serving analyses start by exaggerating as much as possible the cost to society of the ailment to be treated. The risks associated with the new drug are severely underestimated, which results in an extremely favorable risk-benefit analysis, which is almost never realized once the drug is on the market. Experts who can produce highly favorable risk-benefit analyses are very much in demand, however.”